(NASDAQ: XBIO) Xenetic Biosciences's forecast annual revenue growth rate of -6.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 18.69%.
Xenetic Biosciences's revenue in 2026 is $3,260,777.On average, 3 Wall Street analysts forecast XBIO's revenue for 2026 to be $7,170,134, with the lowest XBIO revenue forecast at $6,888,952, and the highest XBIO revenue forecast at $7,381,020.
In 2027, XBIO is forecast to generate $5,975,112 in revenue, with the lowest revenue forecast at $5,740,793 and the highest revenue forecast at $6,150,850.